Targeting of nuclear Factor-κB and proteasome by dithiocarbamate complexes with metals

被引:121
|
作者
Cvek, B. [1 ]
Dvorak, Z. [1 ]
机构
[1] Palacky Univ, Fac Med & Dent, Dept Med Chem & Biochem, CR-77147 Olomouc, Czech Republic
关键词
disulfiram; diethyldithiocarbamate (DDTC); pyrrolidinedithiocarbamate (PDTC); metal dithiocarbamates; NF-kappa B; proteasome; JAMM;
D O I
10.2174/138161207782110390
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-kappa B (NF-kappa B) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-kappa B plays a central role in the immune system and is described as major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-kappa B pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-kappa B signal transduction were recognized, Additionally, proteasome system was found to be a key player in NF-kappa B pathway and is an attractive target for anticancer drug development Collectively, the capability of dithiocarbamates to inhibit NF-kappa B and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-kappa B signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
引用
收藏
页码:3155 / 3167
页数:13
相关论文
共 50 条
  • [21] Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells
    Ta, Michelle H. T.
    Liuwantara, David
    Rangan, Gopala K.
    BMC NEPHROLOGY, 2015, 16
  • [22] Role of nuclear factor-κB in melanoma
    Amiri, KI
    Richmond, A
    CANCER AND METASTASIS REVIEWS, 2005, 24 (02) : 301 - 313
  • [23] Nuclear factor-κB, cancer, and apoptosis
    Bours, V
    Bentires-Alj, M
    Hellin, AC
    Viatour, P
    Robe, P
    Delhalle, S
    Benoit, V
    Merville, MP
    BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1085 - 1089
  • [24] Regulation of nuclear factor-κB in autoimmunity
    Sun, Shao-Cong
    Chang, Jae-Hoon
    Jin, Jin
    TRENDS IN IMMUNOLOGY, 2013, 34 (06) : 282 - 289
  • [25] Nuclear factor-κB and liver carcinogenesis
    Arsura, M
    Cavin, LG
    CANCER LETTERS, 2005, 229 (02) : 157 - 169
  • [26] Growing old with nuclear factor-κB
    Giardina, C
    Hubbard, AK
    CELL STRESS & CHAPERONES, 2002, 7 (02): : 207 - 212
  • [27] Nuclear factor-κ-B:: The enemy within
    Aggarwal, BB
    CANCER CELL, 2004, 6 (03) : 203 - 208
  • [28] Nuclear factor-κB in rheumatoid arthritis
    Li, Jie
    Tang, Rong-Shuang
    Shi, Zhou
    Li, Jin-Qi
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (12) : 1627 - 1635
  • [29] Role of nuclear factor-κ B in melanoma
    Katayoun I. Amiri
    Ann Richmond
    Cancer and Metastasis Reviews, 2005, 24 : 301 - 313
  • [30] Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear Factor-κB activation
    Park, Jong Woong
    Qi, Wen-Ning
    Cai, Yongting
    Urbaniak, James R.
    Chen, Long-En
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2007, 120 (07) : 1808 - 1818